Skip to Content

Our Pipeline

We are building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.

Programs
In Vivo CRISPR is the therapy
Ex Vivo CRISPR creates the therapy
Program
Research and
Preclinical
Early-Stage
Clinical
Late-Stage
Clinical
Partners
Genetic Diseases
NTLA-2001 (nexiguran ziclumeran**) Transthyretin (ATTR)
Amyloidosis
NTLA-2002 Hereditary
Angioedema
NTLA-3001 AATD-Lung
Disease
Hemophilia A / B***
Research Programs
Research Programs
  • *
Immuno-Oncology / Autoimmune Disease
Research Programs
  • *
  • AATD: alpha-1 antitrypsin deficiency
  • Lead refers to lead development and commercial party
  • * Intellia is advancing both wholly-owned and partnered programs.
  • ** NTLA-2001 is now known as nexiguran ziclumeran (nex-z)
  • *** Hemophilia A program is in the research stage. Hemophilia B is being advanced by Regeneron. Intellia is eligible for milestones and royalties.